Dec. 10, 2015 1:13 PM ET | About: Threshold Pharmaceuticals, Inc. (THLD)
The failure of the phase III study of evofosfamide in soft tissue sarcoma– which was itself only half of an unprecedented double dose of disappointment meted out to Threshold Pharmaceuticals (NASDAQ:THLD) yesterday– has left observers pondering the implications for future development in this cancer field.
Most obviously, Threshold’s discontinuation of evofosfamide leaves an already thin pipeline in this indication even thinner (see table below). And the sarcoma field has never had a very strong flow of new agents.
...